Remove Engineer Remove Genotoxicity Remove In-Vivo Remove Regulation
article thumbnail

FDA’s New Draft Guidance on 510(k) Implant Devices: What You Need to Know

FDA Law Blog

By Philip Won & Véronique Li, Senior Medical Device Regulation Expert — As we recently blogged , FDA released three draft guidance documents to help enhance the predictability, consistency, and transparency of the 510(k) program. One of these documents focuses on “ Evidentiary Expectations for 510(k) Implant Devices.”

In-Vivo 45
article thumbnail

Accelerating NDA filing through faster carcinogenicity assessment

Drug Discovery World

This stage is more highly regulated and consists of both preclinical testing and clinical trials. Until recently, drug carcinogenicity assessment required two different in vivo studies, one of which was typically a two-year lifetime study in rats. Drug discovery and development is an arduous process that can cost upwards of $2.6